NCT06306547|Not Yet Recruiting
Loading search results
Sponsor study identifier
observational
1,000
0 countries
N/A
Study Start
April 1, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
April 1, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
April 1, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Idiopathic inflammatory myositis (IIM), also known as myositis, are a heterogeneous group of diseases characterized by chronic inflammation of striated muscles and skin, with different clinical manifestations, treatment responses, and prognosis. This project will build a clinical follow-up cohort for idiopathic inflammatory myositis (IIM) centered on Renji Hospital, Shanghai Jiao Tong University School of Medicine, to promote the clinical and pathogenesis of this group of diseases.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 1, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 21, 2024
Actual (reported)March 12, 2024
Actual (reported)April 1, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
April 1, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
April 1, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
High Resolution Computed Tomography of Chest
High Resolution Computed Tomography of Chest will be used to assess the incidence of interstitial pneumonia.
three months
Cutaneous Disease Area and Severity Index
Cutaneous Disease Area and Severity Index will be used to assess the the severity of the rash.
three months
Forced vital capacity
t refers to the maximum amount of air that cr trying to inhale as quickly as possible.
three months
Manual Muscle Testing
Manual Muscle Testing will be used to assess patients with muscle weakness.
three months
Forced expiratory volume in one second
It refers to the volume of the maximum exhalation exhaled in the first second of the maximum deep inhalation.
three months
Serum creatine kinase
three months
Patients with IMM will be grouped according to the type of positive myositis-specifc autoantibody,and then again according to whether and what type of tumor they had comorbid.
Patients with IMM will be grouped according to the type of positive myositis-specifc autoantibody,and then again according to whether and what type of tumor they had comorbid.
no interventions were involved
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Aged 18-75 years and eligible for the 2017 European League Against Rheumatism/American College of Rheumatology.
Fu Y, Chen Z, Chen J, Wu W, Gu L, Ma Y, Wang R, Wang K, Xie C, Chen Y, Cai J, Fu Q, Wang X, Ye S. Efficacy of JAK inhibitor combined with protein A immunoadsorption in MDA5+ dermatomyositis with RPILD: A real-world study. Med. 2025 Oct 10;6(10):100802. doi: 10.1016/j.medj.2025.100802. Epub 2025 Sep 8.
First Submitted
February 21, 2024
First Posted
March 12, 2024
Study Start
April 1, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
April 1, 2034
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
April 1, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
March 12, 2024
Record last verified: 2024-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: